Observational studyObesity surgery2026
Impact of Endoscopic Bariatric and Metabolic Therapies on Chronic Kidney Disease in Patients with Impaired Glycemic Control.
Observational study in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObesity and diabetes are established risk factors for renal function decline. While medical and surgical weight loss therapies have demonstrated reno-protective effects, the impact of endoscopic bariatric and metabolic therapies (EBMTs) on renal function remains unknown.
methodsA retrospective observational study was conducted in consecutive adult patients with impaired glycemic control and CKD who underwent EBMTs (primary and revision procedures) at a tertiary care center. The primary outcome was the change in estimated glomerular filtration rate (eGFR) at 12 months. Secondary outcomes included percent total weight loss (%TWL), the proportion of patients achieving ≥5% and ≥10% TWL, change in hemoglobin A1 C (HbA1C), and severe adverse event (SAE) rate. Pre- and post-intervention outcomes were compared using paired t-tests and Wilcoxon signed-rank tests. Linear regression analysis was performed to identify predictors of change in eGFR following EBMTs.
resultsMean age and BMI were 56 ± 12 years and 40.0 ± 7.5 kg/m2, respectively (n = 70). At 12-months, the change in eGFR was not significant, increasing from 71.5 ± 13.6 ml/min/1.73m2 to 73.2 ± 17.6 ml/min/1.73m2 (Δ1.1 ± 11.5 ml/min/1.73m2, p = 0.53), and HbA1C significantly decreased by -0.5 ± 1.2% (p = 0.01). Mean %TWL was 13.4 ± 9.9%. A ≥5% TWL and ≥10% TWL were achieved in 70.0% and 51.4% of patients, respectively. On linear regression analysis, ≥10% TWL was associated with significant improvement in eGFR adjusting for age, sex, baseline BMI, diabetes status, CKD stage, and GLP-1RA use (β = 5.8, 95% CI: 0.4–11.2, p = 0.04). The SAE rate was 1.43%.
conclusionEBMTs appear to stabilize kidney function in patients with impaired glycemic control and CKD, with ≥10% TWL associated with significant improvement in eGFR.
Indexed as
Identifiers
41832390What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.